戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 fied short-term to chronic antibiotic and/or immunomodulatory therapy.
2 gets, and as such are attractive targets for immunomodulatory therapy.
3 hosphate lyase may be a potential target for immunomodulatory therapy.
4 e response of multiple sclerosis patients to immunomodulatory therapy.
5 odels, provides a target for diagnostics and immunomodulatory therapy.
6 rome, suggests a potential narrow target for immunomodulatory therapy.
7 otal of 83 patients had 107 requests for new immunomodulatory therapy.
8 t patients for early and aggressive targeted-immunomodulatory therapy.
9 ty was present in 34%, and 4% were receiving immunomodulatory therapy.
10 ases, including 6 cases that did not require immunomodulatory therapy.
11  of the endotypes and their interaction with immunomodulatory therapy.
12 ncluding biologic agents, and 39 received no immunomodulatory therapy.
13 ell responses supporting its potential as an immunomodulatory therapy.
14 tory gray matter lesions that is amenable to immunomodulatory therapy.
15 ovasculitis that does not seem to respond to immunomodulatory therapy.
16 to select patients most likely to respond to immunomodulatory therapy.
17 ilized to interrogate several aspects of the immunomodulatory therapy.
18  identify patients who may be candidates for immunomodulatory therapy.
19 seizure frequency was associated with use of immunomodulatory therapy.
20 nic demyelinating optic neuropathy on stable immunomodulatory therapy.
21 bidity despite continuous systemic and local immunomodulatory therapy.
22                    IVIg is widely used as an immunomodulatory therapy.
23  combination of systemic corticosteroids and immunomodulatory therapy.
24 ng inflamed eyes being treated with systemic immunomodulatory therapy.
25 g as well as for development of prophylactic immunomodulatory therapy.
26 plastic AIR should be treated with long-term immunomodulatory therapy.
27 IR patients should be treated with long-term immunomodulatory therapy.
28               Thirty-seven patients received immunomodulatory therapy.
29 armacological inhibitors of ion channels for immunomodulatory therapy.
30  a minimum of 3 months following a switch of immunomodulatory therapy.
31 ance can be overcome by autoantigen-specific immunomodulatory therapy.
32 glecs could provide novel targets for cancer immunomodulatory therapy.
33 ur cohort of patients who received frontline immunomodulatory therapy.
34 uveitis when used as an adjuvant to systemic immunomodulatory therapy.
35 (22/25) when used as an adjuvant to systemic immunomodulatory therapy.
36  to identify patients who would benefit from immunomodulatory therapies.
37 inflammation continues with greater focus on immunomodulatory therapies.
38 ma either alone or in combination with these immunomodulatory therapies.
39 hich suggests ZAP-70 as a logical target for immunomodulatory therapies.
40 will be additive or synergistic with current immunomodulatory therapies.
41 of human DCs, presenting a unique target for immunomodulatory therapies.
42 sponse and therefore is a logical target for immunomodulatory therapies.
43 ion, suggesting a direction for pro-tolerant immunomodulatory therapies.
44 with OCD and tic disorders will benefit from immunomodulatory therapies.
45 ating brain disease in individuals receiving immunomodulatory therapies.
46 vident and calls for development of specific immunomodulatory therapies.
47 agnosis of AA might help select patients for immunomodulatory therapies.
48 ample opportunities for developing effective immunomodulatory therapies.
49 hil activation threshold to design promising immunomodulatory therapies.
50  documenting immune responses in studies for immunomodulatory therapies.
51 ssues to better inform future application of immunomodulatory therapies.
52 ing tolerance of skin may require additional immunomodulatory therapies.
53 ction without the requirement of vaccines or immunomodulatory therapies.
54 nment on the final outcome of antibody-based immunomodulatory therapies.
55     These conditions often improve following immunomodulatory therapies.
56 sus 8.1%; P < 0.001), with no differences in immunomodulatory therapies (46.8% versus 47.0%; P = 0.93
57 median age, 8.7 years) received at least one immunomodulatory therapy; 75% had been previously health
58 ddress this issue in the context of lymphoma immunomodulatory therapy, a workshop was convened to pro
59                                              Immunomodulatory therapies aimed at reducing secondary i
60                            New antiviral and immunomodulatory therapies aiming to achieve functional
61  with longer periods of uveitis remission on immunomodulatory therapy alone and drug-free remission.
62             This will help develop potential immunomodulatory therapies and antifibrotic approaches f
63 ditions beyond the liver, while evidence for immunomodulatory therapies and cell therapy-based strate
64 new population niches owing to the advent of immunomodulatory therapies and increased numbers of pati
65 autoantibodies would help justify the use of immunomodulatory therapies and provide insight into the
66 ttern, development of effective antiviral or immunomodulatory therapies and vaccines should become sc
67 lated thrombosis, merit consideration, as do immunomodulatory therapy and complement inhibition.
68 sence of major comorbidities, treatment with immunomodulatory therapy and disruption of the microbiom
69 onparaneoplastic AIR patients with long-term immunomodulatory therapy and that there is enough equipo
70  declining lung function, a poor response to immunomodulatory therapies, and early mortality.
71 ly recalcitrant cases, inability to wean off immunomodulatory therapy, and long-term complications le
72 e of his or her disease for consideration of immunomodulatory therapy, and will require legislation m
73    Individuals living with HIV or undergoing immunomodulatory therapies are at risk for developing PM
74                           Antiangiogenic and immunomodulatory therapies are gaining momentum in the p
75                                              Immunomodulatory therapies are limited by unavoidable si
76     However, attempts at introducing various immunomodulatory therapies as a new treatment strategy h
77 tem cell-derived insulin-producing cells and immunomodulatory therapies, but a limitation is the pauc
78 c immunoglobulins are used as replacement or immunomodulatory therapy, but can transmit clinically im
79                             Although current immunomodulatory therapies can reduce relapse frequency
80  Prospective controlled clinical trials with immunomodulatory therapy can help define future treatmen
81 aking their large-scale expansion for use in immunomodulatory therapies challenging.
82  agent, adjunctive treatment for thrombosis, immunomodulatory therapy, complement inhibition, vascula
83                Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to
84  clinical trials provide hope that available immunomodulatory therapies could have therapeutic potent
85 heson 2014 criteria and LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC) (2016 revised
86 s of monoclonal antibody therapies and other immunomodulatory therapies currently being contemplated
87     Extracorporeal photopheresis (ECP) is an immunomodulatory therapy currently recommended in intern
88                 The effectiveness of initial immunomodulatory therapy (day 0, indicating the first da
89                             The responses to immunomodulatory therapies, defined by changes in modifi
90                          PN may benefit from immunomodulatory therapies directed at Th22-mediated inf
91 entially reversible, justifying early use of immunomodulatory therapy directed at lowering IgG levels
92                          Currently available immunomodulatory therapies do not stop the pathogenesis
93 hose at risk for VUE and the use of specific immunomodulatory therapies during gestation to improve o
94 probably underpins differential responses to immunomodulatory therapy, especially IL-23 inhibition.
95                                  Although 12 immunomodulatory therapies exist, they have only modest
96      Despite the immunogenicity of melanoma, immunomodulatory therapies fail in the majority of patie
97  and mycophenolate mofetil are commonly used immunomodulatory therapies for achieving corticosteroid-
98 d improved design of cytokine based clinical immunomodulatory therapies for cancer and infectious dis
99   The development and establishment of novel immunomodulatory therapies for chronic liver diseases ha
100 s their use in generating effective targeted immunomodulatory therapies for difficult-to-treat cancer
101 ial FTD, warranting further consideration of immunomodulatory therapies for disease modification and
102 evelopment of specific, clinically available immunomodulatory therapies for Graves eye disease.
103 isms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.
104 IDS but also occurs in individuals receiving immunomodulatory therapies for immune-related diseases s
105 by donor human leukocyte antigens (HLA), new immunomodulatory therapies for organ-transplant recipien
106 findings suggest that future studies seeking immunomodulatory therapies for preterm infants should co
107 uman AM are a tractable target for inhalable immunomodulatory therapies for respiratory diseases.
108 forms are currently evaluating antiviral and immunomodulatory therapies for severe influenza, buildin
109  B-cell extrinsic mechanisms when developing immunomodulatory therapies for T1D.
110  This may indicate a role for repurposing of immunomodulatory therapies for the treatment of PMDs by
111  neural injury is instrumental for designing immunomodulatory therapies for this dreadful disease.
112 hese developments highlight the potential of immunomodulatory therapies for treatment of these condit
113 ntifies interleukin-37 as a potential viable immunomodulatory therapy for ADPKD.
114 ent of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede
115 ungal infection, specifically in patients on immunomodulatory therapy for autoimmune disease.
116 nts to patients with HIV and those receiving immunomodulatory therapy for autoimmune disease.
117              There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (C
118  therapeutic potential of IRF8 inhibition as immunomodulatory therapy for inflammatory bowel disease
119 ects of chronic MS and had not been received immunomodulatory therapy for MS.
120                 Lactate could be a promising immunomodulatory therapy for patients with acute organ i
121 ves IAPA and suggest anakinra as a promising immunomodulatory therapy for patients with IAPA.
122 who are considering lymphocytotoxic or other immunomodulatory therapy for RA.
123                  IFN-beta-1b is a first-line immunomodulatory therapy for relapsing-remitting multipl
124 ficant limitations of rhIL-10 as a potential immunomodulatory therapy for sepsis.
125 st that RASSF1A may be a promising target in immunomodulatory therapy for the management of acute hea
126               Recent studies have shown that immunomodulatory therapy for the treatment of rheumatic
127                               The utility of immunomodulatory therapy for this condition remains unkn
128      High-dose i.v. Ig (IVIg) is a prominent immunomodulatory therapy for various autoimmune and infl
129                                              Immunomodulatory therapy given to patients with MIS-C in
130  prevention is needed for patients receiving immunomodulatory therapy, given the considerable case fa
131                  Combining multiple systemic immunomodulatory therapies has been shown to be benefici
132            The introduction of sophisticated immunomodulatory therapies has given renewed hope to man
133         The routine use of targeted systemic immunomodulatory therapies has transformed outcomes for
134                                              Immunomodulatory therapy has been associated with better
135                  Combination of surgical and immunomodulatory therapy has limited success.
136 iduals infected with HIV or taking prolonged immunomodulatory therapies have a heightened risk for de
137                             As a result, new immunomodulatory therapies have been used to treat stero
138                                     Existing immunomodulatory therapies have had limited effects on p
139                            While advances in immunomodulatory therapies have resulted in escalating e
140 ld be aware that patients receiving systemic immunomodulatory therapy have a higher risk of developin
141 ncy, oral corticosteroid use, or nonbiologic immunomodulatory therapy (IMT) use, before and after swi
142                           Concurrent classic immunomodulatory therapy (IMT) was given to 251 patients
143 is (NIU) can require treatment with systemic immunomodulatory therapy (IMT), but it is unclear whethe
144 toplasmosis after the initiation of systemic immunomodulatory therapy (IMT).
145 gs (SAIDs), immunosuppressive therapy drugs (immunomodulatory therapy [IMT]), or biologic response mo
146 in tau and raising concerns about the use of immunomodulatory therapies in AD.
147 luated the relative effectiveness of various immunomodulatory therapies in altering autoantibody repe
148  the potential to guide optimal selection of immunomodulatory therapies in individual patients and mo
149 om existing experience with the use of these immunomodulatory therapies in other conditions and that
150  approaches can be used to tailor adjunctive immunomodulatory therapies in patients with sepsis.
151 firmed by the differential susceptibility to immunomodulatory therapies in vivo.
152       Specific subtypes of FM may respond to immunomodulatory therapy in addition to guideline-direct
153 e implications of these cases for the use of immunomodulatory therapy in CD and the questionable asso
154 ogenesis and may represent novel targets for immunomodulatory therapy in dengue.
155 , we highlight three emerging strategies for immunomodulatory therapy in managing ischemic cardiomyop
156 able in vivo model for examining the role of immunomodulatory therapy in modifying HIV infection.
157                                    Trials of immunomodulatory therapy in these patients is now warran
158 mmunologists prepared to move on to systemic immunomodulatory therapy in those instances where the ch
159 nd includes findings from clinical trials of immunomodulatory therapy, indicating that these interven
160                                              Immunomodulatory therapy involving HTLV-1-infected patie
161                                   The use of immunomodulatory therapy is associated with a lower risk
162              Results indicate that long-term immunomodulatory therapy is associated with better visio
163    RECENT FINDINGS: Use of targeted biologic immunomodulatory therapy is becoming widespread and prov
164                      The issue of attempting immunomodulatory therapy is discussed in view of the pub
165 autoimmune liver disease for which effective immunomodulatory therapy is lacking.
166 detrimental or beneficial, before developing immunomodulatory therapies, it is necessary to better un
167                                              Immunomodulatory therapy leads to superior vision outcom
168 tudy provides further evidence that targeted immunomodulatory therapy may be beneficial in specific p
169 n of oncogene-targeted therapy together with immunomodulatory therapy may be ideal for the developmen
170     Ocular inflammation patients on systemic immunomodulatory therapy may develop pulmonary or dissem
171                                              Immunomodulatory therapy may not always be required.
172  knowledge gaps still to be addressed before immunomodulatory therapies might be applied to at least
173 These data implicate the DLN as a target for immunomodulatory therapy of transplant rejection.
174 ly dominated IMIDs, as well as the effect of immunomodulatory therapies on these outcomes.
175 n evaluating T-cell pathogenesis, developing immunomodulatory therapies or vaccines for HIV, and when
176                    Despite widespread use of immunomodulatory therapies, patients may still face prog
177 those of transfusion recipients or providing immunomodulatory therapies prior to blood product exposu
178                 When CpG was administered as immunomodulatory therapy prior to allergen sensitization
179 nsight into the design of clinical trials of immunomodulatory therapies, ranging from optimal patient
180                                       Whilst immunomodulatory therapies reduce disease activity, the
181                                              Immunomodulatory therapy represents an attractive approa
182 tivitis other than MMP, rather than systemic immunomodulatory therapy, resulting in irreversible clin
183                                              Immunomodulatory therapies should be investigated in adu
184                         17 patients required immunomodulatory therapies, six improved spontaneously,
185  creates new translational possibilities for immunomodulatory therapies, specifically vaginal therapi
186 n inhibition might be a useful supplement to immunomodulatory therapies such as corticosteroids in ON
187 t investigations for diagnosis; conventional immunomodulatory therapies, such as interferon beta and
188 ves have been further studied, and promising immunomodulatory therapies, such as targeted B-cell ther
189 or connective tissue disease-associated ILD, immunomodulatory therapy, such as tocilizumab, rituximab
190                                              Immunomodulatory therapies targeting MMPs in preclinical
191 ted to an underlying medical condition or to immunomodulatory therapies that alter the immune respons
192 d advancements in islet cell replacement and immunomodulatory therapies that are coalescing to enable
193                                        Thus, immunomodulatory therapies that improve CD8(+) T cell im
194 n IPF may enable the development of targeted immunomodulatory therapies that successfully halt or pot
195      Intravenous immunoglobulin (IVIG) is an immunomodulatory therapy that has been studied in severa
196             It highlights targets for future immunomodulatory therapy that may treat and potentially
197     Extracorporeal photophoresis (ECP) is an immunomodulatory therapy that shows promise in stabilizi
198 esponse have fueled considerable interest in immunomodulatory therapy, the role of such agents in cli
199 f disease in older patients, those receiving immunomodulatory therapy, those with comorbid conditions
200 ore, DME could be a potential alternative in immunomodulatory therapies to combat RA and related chro
201  micro- and nanoparticles are often added to immunomodulatory therapies to enhance the triggered immu
202                         Expanding the use of immunomodulatory therapies to include HIV treatment depe
203 gun, with the possibility of designing novel immunomodulatory therapies to intervene with neuroinflam
204 gether, our data highlight the potential for immunomodulatory therapies to stimulate alveologenesis i
205  generate additional directions for systemic immunomodulatory therapies to target fibrosis and other
206 ll be critical for repurposing or developing immunomodulatory therapies to treat obesity and/or T2DM-
207 y IL-1 response could be used as a potential immunomodulatory therapy to improve the outcome of asper
208 e spread of nodal metastases and the role of immunomodulatory therapy to prevent or possibly even rev
209 optive T-cell therapy development as well as immunomodulatory therapy tools available for immediate c
210 nd innovative strategies, including targeted immunomodulatory therapies, tyrosine kinase inhibitors a
211              Emerging evidence suggests that immunomodulatory therapies used in nephrotic syndrome di
212 ficantly influences its response to numerous immunomodulatory therapies used in organ transplantation
213            Prednisone doses before and after immunomodulatory therapy were compared.
214 ectious scleritis refractory to conventional immunomodulatory therapy who were seen at the Massachuse
215                           We anticipate that immunomodulatory therapy will offer exciting opportuniti
216 re critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effect
217           The data support the potential for immunomodulatory therapy with CpG in early life to reduc
218           The patient required dual systemic immunomodulatory therapy with methotrexate and adalimuma
219 en antibiotic treatment, but not biologic or immunomodulatory therapy, with reduced proportions of 11
220                                              Immunomodulatory therapy within the first 24 hours (pati

 
Page Top